Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-23 of 23 for your search:
Start Over
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS142-03, NCI-2015-02095, NCT02325557
Vaccine Therapy in Treating Patients With Prostate Cancer Previously Treated With Surgery or Radiation Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 06-070, NCI-2011-01874, NCT00970203
Prostatic Acid Phosphatase-Sargramostim Fusion Protein or Sargramostim in Treating Patients with Non-Metastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO08801, NCI-2011-00965, H-2008-0073, NCT01341652
Sipuleucel-T with or without Indoximod in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011LS109, NCI-2012-00923, NCT01560923
Sipuleucel-T with or without DNA Vaccine Therapy in Treating Patients with Hormone-Resistant Metastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO11816, NCI-2012-02026, NCT01706458
Sipuleucel-T and Stereotactic Ablative Body Radiation Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 102012-026, NCI-2015-01669, NCT01818986
Enzalutamide with or without Vaccine Therapy in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0146, NCI-2013-01565, 1301-1204, 130146, P121106, RD-13-I-11, 9589, NCT01867333
Vaccine Therapy in Treating Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0112, NCI-2014-02498, P131384, NCT02153918
Immediate or Delayed Ipilimumab after Sipuleucel-T Treatment in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12557, NCI-2014-00318, 079730, CC#12557, NCT01804465
Dendritic Cell Vaccine Therapy in Treating Patients with Stage D0 Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0075, NCI-2015-00171, 150075, P121083, NCT02362451
Docetaxel and PROSTVAC for Metastatic Castration Sensitive Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0048, NCI-2016-00058, 1511-1478, P152467, RD-15-IX-08, NCT02649855
Rilimogene Galvacirepvec and Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine in Preventing Relapse in Patients with Prostate Cancer after Radical Prostatectomy
Status: Active
Phase: Phase II
Type: Prevention, Treatment
Age: 22 and over
Trial IDs: 102377, NCI-2016-01144, NCT02772562
Vaccine Therapy in Treating Patients with HER2-Positive Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0016, NCI-2013-01564, 130016, P12990, NCT01730118
Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: O11-10678, NCI-2014-01906, Department of Defense, NCT02058680
Vaccine Therapy with or without Sargramostim in Treating Patients with Metastatic Prostate Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UW14072, NCI-2015-00808, 2014-1456, NCT02411786
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7791001, NCI-2016-00393, PRCA VBIR FIP STUDY, NCT02616185
Radiation Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 223912, NCI-2013-00633, NCT01833208
Immune Activation in Patients with Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T Immunotherapy
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: Pro00047231, NCI-2015-02074, NCT02036918
Vaccine Therapy and Pembrolizumab in Treating Patients with Hormone-Resistant, Metastatic Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UW15014, NCI-2015-01154, 2015-0453, NCT02499835
Dendritic Cell Vaccine Therapy in Treating Patients with Prostate Cancer Enrolled on NCI 09-C-0139
Status: Enrolling by invitation
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0076, NCI-2015-00172, 150076, P131334, NCT02362464
Rilimogene-Galvacirepvec and Prostvac-V/F in Treating Patients with Biochemical Recurrent Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0035, NCI-2015-02254, 1510-1475, P152347, RD-15-VIII-18, NCT02649439
Start Over